HTLV-II among injecting drug users in Stockholm.
134 injecting drug users (IDUs) treated at the Department of Infectious Diseases of Roslagstull Hospital, Stockholm, were tested for antibodies to human T-lymphotropic virus, types I and II, by means of 2 HTLV-I/-II peptide-based enzyme immunoassays (EIAs), followed by a whole-virus EIA. Positive EIA reactions were checked and typed by electrophoretic immunoblotting with native HTLV-I and recombinant HTLV-I and -II proteins. 10 IDUs were diagnosed as HTLV-II seropositive. All 10 were of Scandinavian descent. Thus, like HIV-1, HTLV-II infection has entered the injecting drug user population in Stockholm.
Department of Immunology, Microbiology, Pathology and Infectious Diseases, Karolinska Institute, Huddinge University Hospital, Stockholm, Sweden.
A
A
Krook
J
J
Blomberg
D000328:Adult; D005260:Female; D015482:HTLV-II Antibodies / Q000097:blood*; D015491:HTLV-II Infections / Q000453:epidemiology*; D006801:Humans; D007124:Immunoenzyme Techniques; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D012703:Serotyping; D015819:Substance Abuse, Intravenous / Q000150:complications*; D013548:Sweden / Q000453:epidemiology
D015482:HTLV-II Antibodies